Immune-mediated hemolytic anemia (IMHA) occurs when the dog's immune system is triggered to attack its own red blood cells. Serious and often fatal blood clots are a major complication of dogs afflicted with IMHA. In the early stages of the disease, heparin is often used as an anticoagulant therapy to prevent blood clots. Researchers will evaluate which of two bedside methods of monitoring heparin therapy provides better therapeutic monitoring and prevention of devastating clotting complications.
Grant amount awarded
North Carolina State University
Rita M. Hanel, DVM, DACVIM ,DACVECC